Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes

Enrolling by invitation · Phase 4

Conditions studied: Type 2 Diabetes Mellitus

In brief

This clinical trial aims to evaluate and compare the comparative efficacy and safety of Metformin-Empagliflozin-Sitagliptin vs. Metformin-Empagliflozin-Linagliptin in newly diagnosed Type 2 Diabetes Mellitus patients. The study will involve 110 participants, aged 30-55, enrolled at the National Medical Centre, Karachi, Pakistan. The study involves two groups, subjects will receive the following treatments: Group A will receive Tab Metformin 1000mg + Tab Empagliflozin 12.5mg (FDC) + Tab Sitagliptin 50mg, whereas Group B will receive Tab Metformin 1000mg + Tab Empagliflozin 12.5mg + Tab Linagliptin 2.5mg (FDC) per orally, once daily, for 90 days. Safety and efficacy will be assessed through anthropometric measurements and lab investigations at baseline, 6 weeks, and 12 weeks, with weekly monitoring of blood sugar levels. The total duration of the study will be 6 months, with a 3-month individual treatment period.

Key facts

Study ID

NCT07452913

Run by

Bahria University

People needed

110

Starts

2026-01-01

Expected to finish

2026-06-30

Last updated by the study team

2026-03-05

Who can join

Age: 30 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and Females
• Age 30-55 years
• HbA1c = ≥ 8.5 <10 mmol/mol (ADA. 2025)
• BMI >18.5- <29.9 (WHO Asian Criteria)
• Treatment naïve patients
• With / without dyslipidemia

You may not qualify if…

• HbA1c >10 mmol/mol
• BMI > 30 kg/m²
• Pregnancy or lactation
• Systemic diseases such as: hypertension, thyroid, liver, renal diseases etc.
• Known allergy or intolerance to Metformin, Empagliflozin, Sitagliptin or Linagliptin.

Where it is running

• National Medical Center Karachi — Karachi, Sindh, Pakistan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.